Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Profit After Tax (2019 - 2025)

Historic Profit After Tax for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$184.9 million.

  • BridgeBio Pharma's Profit After Tax fell 1259.21% to -$184.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$805.7 million, marking a year-over-year decrease of 8053.27%. This contributed to the annual value of -$543.3 million for FY2024, which is 1682.42% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Profit After Tax is -$184.9 million, which was down 1259.21% from -$183.8 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Profit After Tax registered a high of -$2.6 million during Q2 2022, and its lowest value of -$267.4 million during Q4 2024.
  • Moreover, its 5-year median value for Profit After Tax was -$161.0 million (2021), whereas its average is -$147.7 million.
  • Per our database at Business Quant, BridgeBio Pharma's Profit After Tax skyrocketed by 9749.3% in 2022 and then tumbled by 617991.4% in 2023.
  • Over the past 5 years, BridgeBio Pharma's Profit After Tax (Quarter) stood at -$152.3 million in 2021, then increased by 7.69% to -$140.6 million in 2022, then fell by 21.17% to -$170.3 million in 2023, then plummeted by 56.98% to -$267.4 million in 2024, then surged by 30.84% to -$184.9 million in 2025.
  • Its last three reported values are -$184.9 million in Q3 2025, -$183.8 million for Q2 2025, and -$169.6 million during Q1 2025.